Alert detail
FDA Approval: IBRANCE (PALBOCICLIB) — Type 3 - New Dosage Form
Policy ID: FDA-NDA212436Specialty: Multi-specialtyAdded: 6/27/2026Effective: 2019-11-01federal register
Full alert analysis requires a subscription
Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.